Valiant Organics Board Approves Q1 FY27 Results, Reappoints MD, Shifts Office
Valiant Organics reported Q1 FY27 consolidated revenue of ₹23,481.61 lakhs and net profit of ₹2,926.33 lakhs. The Board reappointed Shri Sathiababu K. Kallada as MD for three years from May 24, 2027. The registered office will shift from Mumbai to Palghar, subject to shareholder approval.
The re-appointment of the MD for a significant term and the relocation of the registered office are important corporate actions. The financial results show growth, contributing to a medium impact.
The company reported positive financial results for the quarter and a significant corporate action with the re-appointment of the Managing Director and relocation of its registered office, which are generally viewed positively.
Valiant Organics Limited announced the outcome of its Board Meeting held on August 12, 2026. The Board approved the unaudited standalone and consolidated financial results for the quarter ended June 30, 2026. The company also re-appointed Shri Sathiababu K. Kallada as the Managing Director for a term of three years, effective May 24, 2027, subject to shareholder approval at the upcoming Annual General Meeting. Additionally, the Board approved the shifting of the company's Registered Office from Mumbai to Palghar, Maharashtra, also subject to shareholder approval. The Corporate Office has been relocated to Vikhroli, Mumbai.
The financial results for the quarter ended June 30, 2026, showed consolidated revenue from operations of ₹23,481.61 lakhs and a net profit of ₹2,926.33 lakhs. Standalone revenue from operations was ₹23,418.05 lakhs with a net profit of ₹2,182.27 lakhs.
Shri Sathiababu K. Kallada has over 38 years of experience in the chemical industry and is not related to any other director of the company. The Board meeting commenced at 12:35 PM IST and concluded at 03:50 PM IST.
What to do with a filing like this
Valiant Organics Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Valiant Organics Limited. Read the original for the full detail.